Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma: a randomized, controlled, trial
Open accessThe DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.
Abstract
The US Food and Drug Association has approved interferon-α (IFN-α) and interleukin-2 (IL-2) as adjuvant therapy in malignant melanoma. The objective of the study was to compare efficacy and safety of subcutaneous interferon-α with continuous intravenous IL-2 in Chinese patients with malignant melanoma. A total of 250 patients with unresectable malignant melanoma were subjected to randomized in 1 : 1 ratio. Patients received subcutaneous 9×10 IU/m IFN-α (IFN-α group, n=125) or continuous intravenous 9×10 IU/m IL-2 (IL-2 group, n=125) at every 21 days for 4 months. The response, progression-free survival, overall survival, adverse effects, and cost were evaluated by experts in the field. IL-2 and IFN-α were effective in improvement of malignant melanoma after 4 months of intervention. IL-2 was effective in improving brain metastasis. Patients of the IL-2 group had a higher overall survival (P<0.0001) and a higher progression-free survival (P=0.002) than those of IFN-α group. The IL-2 group reported hypotension, kidney dysfunction, liver dysfunctions, flu-like symptoms, and capillary leak syndrome as adverse effects. IFN-α group reported thrombocytopenia and neutropenia as adverse effects. Healthcare management and expert charges lead to increase in the cost of treatment for IL-2 group patients than IFN-α group (P<0.0001). Continuous intravenous IL-2 should be recommended in relapse-free Chinese patients with malignant melanoma. Level of Evidence: I.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the publications regarding trastuzumab and rituximab, eight other publications were identified that report relative time or cost information for IV versus SC administration (Table 2) [112–119]”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.004 · Cited by 1,858
TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITY
Theofilopoulos, A. N., Baccala, R., Beutler, B., & Kono, D. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115843 · Cited by 1,185
Treatment of metastatic melanoma: an overview.
Bhatia, S., Tykodi, S. S., & Thompson, J. A. (2009) · PubMed · Cited by 666
Mocellin, S., Pasquali, S., Rossi, C. R., & Nitti, D. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq009 · Cited by 527
Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090353 · Cited by 487
Eggermont, A. M., Suciu, S., MacKie, R., Ruka, W., Testori, A., Kruit, W., Punt, C. J., Delauney, M., Sales, F., Groenewegen, G., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67482-x · Cited by 311
Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines
Smith, F. O., Downey, S. G., Klapper, J. A., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Restifo, N. P., Levy, C. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0116 · Cited by 239
Vincenti, F. G., Fervenza, F. C., Campbell, K. N., Encarnación, M. M. D., Gesualdo, L., Nelson, P., Praga, M., Radhakrishnan, J., Sellin, L. K., Singh, A. K., et al. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.03.011 · Cited by 153
Research works printed but not linked: 1
- Bi-xia T Lu S Zhi-hong C Chuan-liang C Xi-nan S Li-li M A phase II clinical trial of recombinant human interleukin-2 in treatment of advanced melanoma. Tumor 2011; 31: 1042– 1046.
Cited by
Photodynamic therapy combined with immunotherapy: Recent advances and future research directions
Warszyńska, M., Repetowski, P., & Dąbrowski, J. M. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215350 · Cited by 150
McCloskey, C., Ortega, M. T., Nair, S., Garcia, M. J., & Manevy, F. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00361-3 · Cited by 66
Diaz, M. J., Mark, I. M., Rodriguez, D., Gelman, B., Tran, J. T., Kleinberg, G., Levin, A., Beneke, A. A., Root, K. T., Tran, A. X. V., et al. (2023) · Life · doi:10.3390/life13030828 · Cited by 26
Zhang, S., Yang, Z. H., & Qi, F. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-05227-2 · Cited by 24
Cytokine Modification of Adoptive Chimeric Antigen Receptor Immunotherapy for Glioblastoma
Pawlowski, K. D., Duffy, J. T., Gottschalk, S. M., & Balyasnikova, I. V. (2023) · Cancers · doi:10.3390/cancers15245852 · Cited by 19
Metadata
- Authors
- Li, S., Wu, X., Chen, P., Pei, Y., Zheng, K., Wang, W., Qiu, E., & Zhang, X.
- Affiliations
- Liaoning Cancer Hospital & Institute (CN)
- China Medical University (CN)
- Corresponding author
- Li, Shenglong
- Wu, Xixi
- Venue
- Anti-Cancer Drugs
- Published
- 2019-04
- Volume
- 30
- Issue
- 4
- Pages
- 402-409
- ISSN
- 0959-4973 (ISSN-L)
- PMC
- PMC6430598
- OpenAlex
- W2995216457
- Cited by
- 11
- References
- 28
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 5 · 2022: 1 · 2021: 1 · 2019: 1
- FWCI
- 0.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Anti-Cancer Drugs (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- interferon-alpha, interleukin-2, melanoma, adjuvant immunotherapy, unresectable melanoma, progression-free survival, overall survival, brain metastases, adverse effects, treatment costs, Chinese patients
- MeSH terms
- Cutaneous Malignant Melanoma, Adult, Antineoplastic Combined Chemotherapy Protocols, Female, Follow-Up Studies, Humans, Interleukin-2, Male, Melanoma, Middle Aged, Prognosis, Skin Neoplasms, Survival Rate, Interferon-alpha, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma: a randomized, controlled, trial. https://app.cochat.ai/papers/10.1097/cad.0000000000000741
- The paper
- Li, S., Wu, X., Chen, P., Pei, Y., Zheng, K., Wang, W., Qiu, E., & Zhang, X. (2019). Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma: a randomized, controlled, trial. Anti-Cancer Drugs. https://doi.org/10.1097/cad.0000000000000741
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.